Literature DB >> 9427647

An oncogenic mutation uncouples the v-Jun oncoprotein from positive regulation by the SAPK/JNK pathway in vivo.

G H May1, M Funk, E J Black, W Clark, S Hussain, J R Woodgett, D A Gillespie.   

Abstract

Stimulation of c-Jun transcriptional activity via phosphorylation mediated by the stress-activated or c-Jun amino-terminal (SAPK/JNK) subgroup of mitogen-activated protein kinases (MAP kinases) is thought to depend on a kinase-docking site (the delta region) within the amino-terminal activation domain, which is deleted from the oncogenic derivative, v-Jun [1] [2] [3]. This mutation markedly enhances v-Jun oncogenicity [4] [5]; however, its transcriptional consequences have not been resolved. In part, this reflects uncertainty as to whether binding of SAPK/JNK inhibits c-Jun function directly [6] [7] or, alternatively, serves to facilitate and maintain the specificity of positive regulatory phosphorylation [8]. Using a two-hybrid approach, we show that SAPK/JNK stimulates c-Jun transactivation in yeast and that this depends on both catalytic activity and physical interaction between the kinase and its substrate. Furthermore, c-Jun is active when tethered to DNA via SAPK/JNK, demonstrating that kinase binding does not preclude transactivation. Taken together, these results suggest that SAPK/JNK acts primarily as a positive regulator of c-Jun transactivation in situ, and that loss of the docking site physically uncouples v-Jun from this control. This loss-of-function model accounts for the deficit of v-Jun regulatory phosphorylation and repression of TPA response element (TRE)-dependent transcription observed in v-Jun-transformed cells and predicts that an important property of the oncoprotein is to antagonise SAPK/JNK-dependent gene expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427647     DOI: 10.1016/s0960-9822(98)70043-0

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  6 in total

1.  Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation.

Authors:  S l Fu; I Bottoli; M Goller; P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

2.  v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity.

Authors:  W Clark; E J Black; A MacLaren; U Kruse; N LaThangue; P K Vogt; D A Gillespie
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

3.  Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside).

Authors:  Yutaka Miura; Mami Kainuma; Hao Jiang; Hershey Velasco; Peter K Vogt; Senitiroh Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-08       Impact factor: 11.205

4.  The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation.

Authors:  S J Cook; N Aziz; M McMahon
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

5.  Repression of yeast Ste12 transcription factor by direct binding of unphosphorylated Kss1 MAPK and its regulation by the Ste7 MEK.

Authors:  L Bardwell; J G Cook; D Voora; D M Baggott; A R Martinez; J Thorner
Journal:  Genes Dev       Date:  1998-09-15       Impact factor: 11.361

6.  AP1 genes in Fugu indicate a divergent transcriptional control to that of mammals.

Authors:  Amanda J Cottage; Yvonne J K Edwards; Greg Elgar
Journal:  Mamm Genome       Date:  2003-08       Impact factor: 2.957

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.